Treatment type
Tryngolza (olezarsen) — ApoC-III ASO for severe hypertriglyceridemia (sHTG) and FCS
Tryngolza (olezarsen) is a monthly shot. In June 2026, the United States approved it for adults with severe high triglycerides.
This is for adults with severe hypertriglyceridemia (fasting TG 500 mg/dL or higher) — and caregivers — who need a labelled way to lower triglycerides and cut…
Onswik (insulin efsitora alfa-gobe) — once-weekly basal insulin for adults with type 2 diabetes
Onswik (insulin efsitora alfa) is a once-weekly long-acting insulin for adults with type 2 diabetes.
This is for adults with type 2 diabetes — and caregivers helping them — who may be candidates for a once-weekly basal insulin instead of a daily basal shot.
Mounjaro (tirzepatide) — weekly shot for adults with type 2 diabetes that now also carries a labelled heart-protection use
FDA supplemental approval effective 27 August 2026 for a new use of Mounjaro (tirzepatide) injection — a once-weekly subcutaneous dual GIP/GLP-1 receptor…
This is for adults with type 2 diabetes who are at high risk for heart attack, stroke, or cardiovascular death, and who may already be candidates for weekly…
Trutakna (atacicept-vymj) — weekly under-the-skin shot to lower protein in the urine in adults with primary IgA nephropathy
FDA accelerated approval on 7 July 2026 for Trutakna (atacicept-vymj) injection — a weekly subcutaneous medicine — to reduce proteinuria in adults with primary…
This is for adults with primary IgA nephropathy who leak protein into the urine and may be candidates for labelled US Trutakna once-weekly home shots.
Lytenava (bevacizumab-vikg) — ophthalmic VEGF inhibitor injection for wet age-related macular degeneration
FDA approval on 24 July 2026 for Lytenava (bevacizumab-vikg) injection — an ophthalmic VEGF inhibitor for intravitreal use — for neovascular (wet) age-related…
This is for adults with wet age-related macular degeneration who may be candidates for labelled US Lytenava monthly eye injections — the first FDA-approved…
Zycubo (copper histidinate) — subcutaneous copper replacement for Menkes disease in pediatric patients
FDA approval on 12 January 2026 for Zycubo (copper histidinate) for injection — a subcutaneous copper replacement — for Menkes disease in pediatric patients.
This is for families of children with Menkes disease who may be candidates for labelled US Zycubo subcutaneous copper replacement — especially when treatment…
Imaavy (nipocalimab-aahu) — neonatal Fc receptor blocker for warm autoimmune hemolytic anemia in adults and adolescents 12 years and older after corticosteroid exposure
FDA approval on 25 August 2026 for Imaavy (nipocalimab-aahu) injection — a neonatal Fc receptor (FcRn) blocker — for warm autoimmune hemolytic anemia (wAIHA)…
This is for people 12 years and older with warm autoimmune hemolytic anemia who are currently on or have previously received corticosteroids and who may be…
Yuviwel (navepegritide) — once-weekly CNP analog for children ≥2 with achondroplasia
FDA accelerated approval on 27 February 2026 for Yuviwel (navepegritide) for injection — a C-type natriuretic peptide (CNP) analog / TransCon CNP prodrug — to…
This is for families of children aged 2 years and older with achondroplasia and open growth plates who may be candidates for a labelled US once-weekly…
Awiqli (insulin icodec / insulin icodec-abae) — once-weekly basal insulin
The first labelled once-weekly basal insulin.
Awiqli (insulin icodec) is a once-weekly long-acting insulin. The United States approved it in March 2026 only for adults with type 2 diabetes.
Zanvastro (zilganersen) for Alexander disease (AxD)
The first FDA-labelled medicine for Alexander disease — an ultra-rare, progressive GFAP leukodystrophy.
Zanvastro (zilganersen) is the first approved medicine for Alexander disease, a very rare brain disease.
Hepcludex (bulevirtide) for chronic hepatitis D (HDV)
The first labelled drug for chronic hepatitis D. The United States (FDA accelerated, 22 May 2026) labels 8.5 mg subcutaneously once daily for adults without…
Hepcludex (bulevirtide) is the first approved medicine for chronic hepatitis D. The United States gave accelerated approval to a daily 8.5 mg shot in May 2026.…
Exdensur (depemokimab) for severe eosinophilic asthma — and, outside the United States, for nasal polyps
The FDA, Health Canada, the UK MHRA, Japan’s MHLW, the EU Commission, and (on the Australian PI) the TGA have labelled a twice-yearly anti-IL-5 injection.
Exdensur (depemokimab) is a shot given twice a year for severe eosinophilic asthma. In the United States, it is approved for this asthma in people 12 and older.
Mimrylo (rusfertide) for erythrocytosis in adults with polycythemia vera (PV)
The FDA labelled a once-weekly subcutaneous hepcidin mimetic for adults with polycythemia vera who still need frequent phlebotomies despite standard care.
Fasenra (benralizumab) for hypereosinophilic syndrome
Health Canada and the FDA have labelled Fasenra for hypereosinophilic syndrome. Japan and Switzerland have too. The UK SmPC already carries the wording.